Boston, MANCT07104331Now EnrollingIRB Ready

Epithelioid Hemangioendothelioma Clinical Trial in Boston, MA

Access cutting-edge epithelioid hemangioendothelioma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Sarcoma Alliance for Research through Collaboration

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access epithelioid hemangioendothelioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related epithelioid hemangioendothelioma treatment provided free

Apply for This Boston Location

Check if you qualify for this epithelioid hemangioendothelioma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Epithelioid Hemangioendothelioma Study in Boston

This is a non-randomized, open label, single arm Phase II trial with a two-stage design with histologically-confirmed metastatic and/or recurrent epithelioid hemangioendothelioma requiring systemic treatment. nab-Sirolimus 100 mg/m2 will be administered as an intravenous infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. The primary objective is to determine ORR by RECIST v1.1 of nab-sirolimus in patients with EHE who require systemic treatment.

Sponsor: Sarcoma Alliance for Research through Collaboration

Who Can Participate

Inclusion Criteria

Participants must have histologically or cytologically confirmed EHE that is either progressing or clinically symptomatic, not a candidate for curative intent surgery, and requires systemic therapy in the opinion of the investigator.
Participants must have measurable disease by RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.
Age ≥18 years
ECOG performance status ≤2
Participants must meet the following organ and marrow function as defined below:
Platelets \>75,000μl
ANC \>1500μl
Hgb \>9g/dl
Creatinine \<1.5 x ULN or measured CrCl of \>30ml/m2/1.73 m2
Total bilirubin \<2 x ULN
AST/ALT \<3 x ULN
Patients must h

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07104331) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Epithelioid Hemangioendothelioma Treatment Options in Boston, MA

If you're searching for epithelioid hemangioendothelioma treatment options in Boston, MA, this clinical trial (NCT07104331) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced epithelioid hemangioendothelioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all epithelioid hemangioendothelioma clinical trials near you to find additional studies recruiting in your area.

More Osteogenesis Imperfecta Trials in Boston, MA

See all osteogenesis imperfecta clinical trials recruiting in Boston — not just this study.

Browse Osteogenesis Imperfecta Trials in Boston →

Browse More Trials by Condition

Osteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA